
Subject **Programme and Policy Committee Chair Report**

Category **For Information**

Section A: Introduction

- This report provides the Board with an overview of the activities of the Programme and Policy Committee (PPC) since the Committee Chair last reported to the Board in December 2022.
- On 16-17 May 2023, the PPC held an in-person meeting. During the meeting, the Committee discussed a number of important topics for the Alliance and agreed on recommendations which are being put forward to the Board at its 26-27 June 2023 meeting for consideration.
- The PPC Chair report is attached in the form of a presentation as Annex A and the PPC recommendations to the Board are attached as Annex B.

Annexes

Annex A: PPC Chair report

Annex B: 16-17 May 2023 recommendations to Gavi Alliance Board

PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

BOARD MEETING

Anne Schuchat

26-27 June 2023, Geneva, Switzerland

PPC Meeting, 16-17 May 2023

Discussion, Information and Guidance Items

- CEO Update
- COO Update and Read-Out from Audit & Finance Committee (AFC) Meeting
- Country Programmes Delivery Presentation
- Vaccine Investment Strategy 2018

PPC Meeting, 16-17 May 2023

Recommendations to the Board

- Strategy, Programmes and Partnerships: Progress, Risks and Challenges (*Board Agenda Item 2*)
- Hexavalent Investment Case (*Board Agenda Item 6*)
- COVAX Update and Gavi's Role in a future COVID-19 Vaccine Programme (*Board Agenda Item 7*)
- Vaccine Investment Strategy 2024 (*Board Agenda Item 8*)
- Gavi's Role in Pandemic Prevention, Preparedness and Response (*Board Agenda Item 9*)

PPC Meeting, 16-17 May 2023

CEO Update

- Noting this as his last PPC meeting, Committee members thanked the CEO and expressed deep appreciation for his work and support to the PPC during his tenure.
- Welcomed flexibilities granted to countries to reallocate existing funds for catch-up and recovery plans and highlighted the need to focus on the big catch-up to reach those children missed during the COVID-19 pandemic.
- Raised concerns around both the supply of new vaccines and the increasing cases of measles, emphasising the need for urgent prevention strategies.
- Highlighted the importance of prioritising the Gavi core mission and provide the Board with clear information regarding trade-offs involved in key investment decisions, such as taking a life course approach to immunisation.
- Noted the cross-Alliance efforts to address the complexities associated with rolling out the malaria vaccine.
- Reflected on the value of the recently signed Memorandum of Understanding (MoU) with the African Union (AU).

PPC Meeting, 16-17 May 2023

COO Update and Read-Out from Audit & Finance Committee (AFC) Meeting

- Welcomed the information provided by the Chief Operating Officer (COO) on the balanced scorecard and overall operational excellence agenda.
- Commended the focus on accelerating disbursements to countries and the cross-topic view provided by the COO, and noted the need for a clear overview of approach allocation and resource distribution across different programmes.
- Suggested the balance scorecard include a separate risk module, information on enhanced transition preparedness risks, and reporting on the percentage of HSIS (health system and immunisation strengthening) funds flowing through government systems.
- Emphasised the importance to have Alliance partners on board as different vaccines are rolled out, and the need to resume discussions on partner roles and responsibilities.

PPC Meeting, 16-17 May 2023

Country Programmes Delivery Presentation

- Appreciation for joint presentation by Secretariat, WHO and UNICEF that fully demonstrated the strength of the Alliance
- Endorsed the proposed approach to temporarily revise the current risk appetite related to preventative measles campaigns and suggested that PPC should further discuss measles going forward, with a focus on exploring the use of campaigns, risk appetite, the evidence based and potential investment options
- Noted discussions on the annual review and implementation of the gender policy at PPC meeting in October 2023

PPC Meeting, 16-17 May 2023

Vaccine Investment Strategy 2018

- Unpausing
- Sequencing vs. offering menu
 - Simplify application & review process, use existing technical resources
 - Facilitate vaccine introductions earlier than 2026 per country demand
- Level of ambition feedback

PPC Meeting, 16-17 May 2023

Recommendations to the Board

- Listed in Annex B
- Further details from the PPC discussions contained in the relevant papers to the Board (indicated on slide 3)

Thank you

REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE
16-17 May 2023, Geneva, Switzerland

Decision 1: Strategy, Programmes and Partnerships: Progress, Risks and Challenges

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

Approve a two-year extension to the US\$ 500 million in Equity Accelerator Funding (EAF) approved by the Board enabling countries to receive EAF disbursements until 2027, recognising that the COVID-19 pandemic has delayed design and implementation of EAF grants.

Decision 2: COVAX Update and Gavi's Role in a future COVID-19 Vaccine Programme (1/2)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** US\$ 711 million from the COVAX AMC for a new programme for COVID-19 vaccination in 2024-2025 contingent on:
 - a. Continuation of the WHO base-case scenario for the pandemic evolution requiring continued focus on high priority groups as per SAGE recommendation; and
 - b. Sufficient funding as confirmed by the Board in June 2023
- b) **Approve** the following country scope and extent of support for a 2024-2025 COVID-19 vaccine programme:
 - a. Country scope: AMC91 (Gavi54 and AMC37)
 - b. Extent of support:
 - i. Gavi54: Eligible for full vaccine procurement support without co-financing obligations and eligible for delivery support **through existing CDS resources** (~~consisting of the provision of 70% of estimated total delivery costs for the vaccines~~)
 - ii. AMC37: Eligible for vaccine catalytic financing in line with the MICs Approach for vaccine procurement and ~~not~~ eligible for delivery support **through existing CDS resources**

Decision 2: COVAX Update and Gavi's Role in a future COVID-19 Vaccine Programme (2/2)

The Gavi Alliance Programme and Policy Committee:

- a) **Noted** that Gavi will cease to administer the COVAX Facility beyond 31 December 2023, with the COVAX Facility ending in accordance with its terms on or prior to such date.
- b) **Noted** that despite Gavi no longer administering the COVAX Facility beyond 31 December 2023, provision of COVID-19 vaccines would continue through Gavi per the proposed 2024-2025 COVID-19 vaccine programme, pending Board approval.
- c) **Noted** that the Alliance would provide guidance on COVID-19 programmatic integration and considerations for transition to the 2024-2025 COVID-19 vaccine programme, pending Board approval, as outlined in Part I, paragraph 2; and
- d) **Noted** that delivery funding for the 2024-2025 COVID-19 vaccine programme will be through a no-cost extension of COVID-19 Delivery Support.

Decision 3: Hexavalent Investment Case (1/2)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the opening of a funding window for Hexavalent vaccine for the administration of diphtheria, tetanus, whole-cell pertussis, hepatitis B, Haemophilus influenza b (Hib), and IPV antigens;
- b) **Note** that the initial estimates of the financial implications associated with the above approval for 2023-2025 are expected to be up to US\$ 62 million, and the US\$ 29 million estimated costs associated with base demand has been taken into account in the financial forecast to be presented to the Board in June 2023;
- c) **Note** that the initial estimates of the financial implications associated with the above approval for 2023-2025 for additional operational cost support and Secretariat and partner resources will be accounted for in the financial forecast to be presented to the Board in December 2023, following consultations with partners and countries;

Decision 3: Hexavalent Investment Case (2/2)

- d) **Note** that the initial estimates of the financial implications associated with the above approval for the strategic period 2026-2030 are expected to be up to US\$ 430 million and contingent on financial resources being made available for the next strategic period; and
- e) **Note** that the initial estimates of the financial implications for both time periods are based on a fully loaded vaccine price and include saved ancillary costs and a one-time switch grant.

Decision 4: Vaccine Investment Strategy 2024: Longlist and Evaluation Frameworks (1/2)

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- a) **Approve** the longlist of pathogens (hepatitis E, m-pox, dengue, COVID-19, tuberculosis, group B streptococcus, chikungunya, and shigella) with licensed or pipeline products, to assess as new potential investments in vaccines and immunisation products through the VIS (Vaccine Investment Strategy) process;
- b) **Approve** the evaluation criteria for potential new investments in vaccines and other immunisation products primarily intended for ***endemic disease prevention***; these include key ranking criteria (health impact, value for money, equity and social protection, Gavi's comparative advantage and economic impact) and modulating criteria that inform the ranking (global health security impact, other impact, broader health system benefits, implementation feasibility, alternative interventions, and contribution to global agenda);

Decision 4: Vaccine Investment Strategy 2024: Longlist and Evaluation Frameworks (2/2)

- c) **Note** the evaluation approach for potential new investments in vaccines and other immunisation products primarily intended for *epidemic disease prevention*; centred around four key questions: i) disease burden and risk, ii) vaccine impact and feasibility, iii) fit for Gavi and partners, and iv) financial implications; and
- d) **Request** as part of the VIS, the Secretariat undertake further analyses to evaluate the potential value of providing support to develop, strengthen and deliver vaccines at new touchpoints for specific target populations building upon lessons learned from other Gavi programmes.

Decision 5: Gavi's role in Pandemic Prevention, Preparedness and Response

Noting that the Secretariat plans to return to the PPC in October 2023 and the Gavi Board in December 2023 with a fully scoped proposal for Gavi in GVPI, which would include, inter alia, confirmation of the role of Gavi and other partners and a financial assessment with a suggested cost envelope, the Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Approve, a time limited envelope until the December 2023 Board meeting of up to US\$ 10 million, for GVPIs for Ebola Sudan and Marburg vaccines if there is a need and an explicit ask from WHO and/or CEPI to Gavi. Any individual agreements with manufacturers would require Phase II data for Ebola Sudan or Marburg candidate vaccines to be available. The individual agreements would be subject to review and approval of Gavi's Market-Sensitive Decisions Committee. This decision would not set a precedent for future Gavi investments.

Thank you